While nausea, vomiting, and diarrhea are common with semaglutide therapy, severe or persistent symptomsparticularly if they differ from your usual experienceshould be evaluated
While safety within the phase 3 program is sufficient for marketing authorization (although the risk of cardiovascular events should not exceed a hazard ratio of 1.8 according to a guidance document that was released by the FDA at that time), it is the post-marketing phase in which rare adverse events and any other potential safety risks are identified or resolved
In that case the rule is: wait out the TE component first, then treat the AGA in a targeted way
Non-invasive ultrasonic modulation of visual evoked response by GABA delivery through the blood brain barrier
It's not enough for brands to encourage more water intake, Lim wrote in the report
Tuersun A, Hou G, Cheng G